BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1436@azbio.org DTSTART;TZID=America/Phoenix:20200421T080000 DTEND;TZID=America/Phoenix:20200421T090000 DTSTAMP:20200331T203131Z URL:https://www.azbio.org/events/azbiopeers-fundraising-tales-from-the-roa d-webcast SUMMARY:AZBioPEERS: Fundraising Tales From The Road - Webcast - Webinar - 21 Apr 20 08:00 DESCRIPTION:\n\nAs the situation with COVID-19 continues to develop\, AZBio is working closely with our state and federal partners to support our mem bers and our community. \;One of our community’s key public health s trategies at this time is social distancing and our industry is leading by example. \;\n\nFor this reason\, the AZBio PEERS Meeting \; on Ap ril 21\, 2020 will be offered a virtual meeting format only.\n\nDate:  \;  \;  \;  \;  \; Tuesday\, April 21\, 2020\n\nTime:  \;  \;  \;  \;  \;8:00 AM – 9:00 AM\n\nFormat: \; Vi rtual Meeting – Webinar\n\nCost: \; Complimentary – Registration R equired\n\nRemote Access Instructions:\nMeeting URL\nhttps://bluejeans.com /316906958?src=join_info\nMeeting ID\n316 906 958\nWant to dial in from a phone?\nDial one of the following numbers:\n+1.888.240.2560 (US Toll Free) \n(see all numbers -https://www.bluejeans.com/premium-numbers)\nEnter the meeting ID and passcode followed by #\n \;\nRegister today to reserve your spot!\n\n \;\n \;\nAbout Our Speaker:\nSteve Potts\, PhD\, MB A (Founder &\; CEO) leads OncoMyx. Steve has worked in the biopharma in dustry since 1999 and has had experience in a wide range of areas\, includ ing product development\, sales\, marketing\, and general management. He h as a proven track record of success\, with his last three companies all wi th significant shareholder returns. He was Vice President of Medical Affai rs at Ignyta\, which was acquired by Roche for $1.7B\, and he led the glob al operation of the testing of 30\,000 patients in an oncology basket tria l for entrectinib in 15 countries. The molecule was the first in industry to receive breakthrough designation equivalents in USA\, Europe\, and Japa n. Prior to Ignyta\, he bootstrapped his first company as founding CEO\, F lagship Biosciences\, to 75 employees and an exit for his investors. He wa s General Manager Life Sciences at Aperio\, which exited to Danaher for $1 80M. He also built the Bioinformatics Department for a Fortune 500 Company \, Quest Diagnostics\, which subsequently delivered $1B of annual revenue. He earned a BS in Physics from Wheaton College\, Illinois and PhD in Biol ogical Engineering and MBA from the University of California Davis.\nAbout Oncomyx\n\n\nOncoMyx Therapeutics is developing oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune respon se and treat cancer. Successful immuno-oncology (IO) cancer treatment gene rally requires combination therapy\, and oncolytic viruses (OVs) have emer ged as a safe and effective IO complement.\n\n\n\n\nOur MYXV platform\, sp un-out from Arizona State University (ASU)\, is poised to be a best-in-cla ss OV approach. We have assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit of cancer patients.\n\n \n \;\n\n\n\n\nWebcasting support provided by the Flinn Foundation\ n\n CATEGORIES:AZ - Central,AZ - North,AZ- South,webinars LOCATION:Webinar\, Anywhere\, USA\, United States X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Anywhere\, USA\, United Sta tes;X-APPLE-RADIUS=100;X-TITLE=Webinar:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20190422T080000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR